DCOY — Decoy Therapeutics Inc.

Salarius Pharmaceuticals (DCOY) Q2 2022 Earnings Call Summary

1. Key Financial Results and Metrics:

• Net Loss: $4.7 million ($0.09 per share) for Q2 2022, compared to $3.1 million ($0.07 per share) in Q2 2021.
• Year-to-Date Net Loss: $10.8 million ($0.22 per share) for the first half of 2022, up from $4.9 million ($0.13 per share) in the same period of 2021.
• Research and Development Expenses: Increased to $2.9 million in Q2 2022 from $2.1 million in Q2 2021, primarily due to spending on targeted protein degradation technology.
• General and Administrative Expenses: Rose to $1.8 million from $1.6 million year-over-year, attributed to higher personnel costs.
• Cash Position: As of June 30, 2022, cash and cash equivalents totaled $22.6 million, down from $29.2 million at the end of 2021, expected to fund operations into 2023.

2. Strategic Updates and Business Highlights:

• Continued progress in clinical trials for seclidemstat, a reversible LSD1 protein inhibitor, with enrollment in a Phase 1/2 study for Ewing’s and FET-rearranged sarcomas.
• Collaboration with Volition Rx for rapid epigenetic profiling to assess drug activity in patients, with data collection expected by year-end.
• Development of SP-3164, a targeted protein degrader, is on track for an IND submission in the first half of 2023, following successful pre-IND meetings with the FDA.
• Attendance at the 2022 BIO International Conference to engage with pharmaceutical companies and gather feedback on clinical data requirements.

3. Forward Guidance and Outlook:

• Anticipation of interim clinical data from the seclidemstat trials later in 2022, with potential positive impacts on treatment options for patients with high unmet needs.
• Plans to provide updates on preclinical data for SP-3164 later this year, with clinical trials expected to commence soon after IND submission.
• Future conference calls will be event-driven, focusing on significant clinical or preclinical data releases rather than adhering to a fixed schedule.

4. Bad News, Challenges, or Points of Concern:

• Increased net loss and operational expenses compared to the previous year, with no grant revenue recorded in 2022, contrasting with $1.8 million in the first half of 2021.
• The absence of grant revenue may impact financial stability and resource allocation for ongoing and future projects.
• The competitive landscape for protein degradation therapies is intensifying, with large pharmaceutical companies actively pursuing partnerships in this area.

5. Notable Q&A Insights:

• Enrollment Status: Enrollment for the seclidemstat trial is progressing well, with the addition of several prestigious clinical sites. Specific enrollment numbers were not disclosed.
• Data Dissemination: Interim data will likely be released via press release or at conferences, depending on the readiness and ethical considerations surrounding the information.
• IND Enabling Studies: SP-3164's IND enabling studies are underway, with a focus on mechanism of action and proof of concept data expected to be presented at an upcoming conference.

Overall, Salarius Pharmaceuticals is positioned for a potentially impactful second half of 2022, with ongoing clinical trials and strategic partnerships, despite facing financial challenges and a competitive market landscape.